摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-methyl-1,6-naphthyridine-5(6H)-one | 35969-61-0

中文名称
——
中文别名
——
英文名称
7-methyl-1,6-naphthyridine-5(6H)-one
英文别名
7-methyl-6H-[1,6]naphthyridin-5-one;7-Methyl-6H-[1,6]naphthyridin-5-on;7-methyl-1,6-naphthyridin-5(6H)-one;7-Methyl-1, 6-naphthyridine-5 (6H)-one;7-methyl-6H-1,6-naphthyridin-5-one
7-methyl-1,6-naphthyridine-5(6H)-one化学式
CAS
35969-61-0
化学式
C9H8N2O
mdl
MFCD18802765
分子量
160.175
InChiKey
SVXFJPJHTJQGEQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    245 °C(Solv: methanol (67-56-1))
  • 沸点:
    412.2±45.0 °C(Predicted)
  • 密度:
    1.201±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.7
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.111
  • 拓扑面积:
    42
  • 氢给体数:
    1
  • 氢受体数:
    2

SDS

SDS:505c93d6e539bcb4e725ff9482392da5
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Ready access to 7,8-dihydro- and 1,2,3,4-tetrahydro-1,6-naphthyridine-5(6<i>H</i>)-ones from simple pyridine precursors
    作者:H. D. Hollis Showalter
    DOI:10.1002/jhet.5570430525
    日期:2006.9
    Short pathways are described for the synthesis of a representative example of each of the 7,8-dihydro-and 1,2,3,4-tetrahydro-1,6-naphthyridine-5(6H)-one ring systems from simple pyridine precursors. An attempted synthesis of the related 4,6-dihydro-1,6-naphthyridin-5(1H)-one ring system from a common intermediate was unsuccessful.
    描述了由简单的吡啶合成7,8-二氢和1,2,3,4-四氢-1,6-萘吡啶-5(6 H)-一环系统中的每一个的代表性实例的短路径前体。从常见的中间体尝试合成相关的4,6-二氢-1,6-萘啶5(1 H)-环系统是不成功的。
  • SUBSTITUTED 2- AMIDOQUINAZOL-4-ONES AS MATRIX METALLOPROTEINASE-13 INHIBITORS
    申请人:Takeda Pharmaceutical Company Limited
    公开号:US20150329556A1
    公开(公告)日:2015-11-19
    The present invention provides a novel amide derivative having a matrix metalloproteinase inhibitory activity, and useful as a pharmaceutical agent, which is a compound represented by the formula (I) wherein ring A is an optionally substituted, nitrogen containing heterocycle, ring B is an optionally substituted monocyclic homocycle or an optionally substituted monocyclic heterocycle, Z is N or NR 1 (R 1 is a hydrogen atom or an optionally substituted hydrocarbon group), is a single bond or a double bond, R 2 is a hydrogen atom or an optionally substituted hydrocarbon group, X is an optionally substituted spacer having 1 to 6 atoms, ring C is (1) an optionally substituted homocycle or (2) an optionally substituted heterocycle other than a ring represented by (II) (X′ is S, O, SO, or CH 2 ), and at least one of ring B and ring C has substituent(s), provided that N-(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]2 hydroxypropyl}5,6 dimethyl 4 oxo 1,4 dihydrothieno[2,3-d]pyrimidine-2-carboxamide is excluded, or a salt thereof.
    本发明提供了一种新型酰胺衍生物,具有基质金属蛋白酶抑制活性,并且作为药用剂是有用的,该化合物由以下式(I)表示,其中环A是一个可选择取代的含氮杂环,环B是一个可选择取代的单环同核环或可选择取代的单环杂环,Z是N或NR1(R1是氢原子或可选择取代的碳氢基团),是一个单键或双键,R2是氢原子或可选择取代的碳氢基团,X是一个具有1到6个原子的可选择取代的间隔物,环C是(1)一个可选择取代的同核环或(2)一个除了由(II)表示的环之外的可选择取代的杂环(X′是S、O、SO或CH2),并且环B和环C中至少有一个有取代基,但不包括N-(1S,2R)-1-(3,5-二氟苄基)-3-[(3-乙基苄基)氨基]2-羟基丙基}5,6-二甲基-4-氧代-1,4-二氢噻唑并[2,3-d]嘧啶-2-羧酰胺,或其盐。
  • 3,4-disubstituted-phenylsulphonamides and their therapeutic use
    申请人:Chiroscience Limited
    公开号:US05728712A1
    公开(公告)日:1998-03-17
    3,4-Disubstituted-phenylsulphonamides have therapeutic utility via TNF or phosphodiesterase inhibition.
    3,4-二取代苯磺酰胺通过抑制TNF或磷酸二酯酶具有治疗作用。
  • Methods, compounds and compositions for treating gout
    申请人:——
    公开号:US20020019417A1
    公开(公告)日:2002-02-14
    This invention relates to methods of preventing, treating or lessening verity of gout by administration of PARP inhibitors.
    这项发明涉及通过给予PARP抑制剂来预防、治疗或减轻痛风的方法。
  • Dihydro- and tetrahydronaphthyridines
    申请人:Warner-Lambert Company
    公开号:US05391554A1
    公开(公告)日:1995-02-21
    This invention concerns novel dihydro- and tetrahydronaphthyridines useful for enhancing the lethal effects on tumor cells to treatment causing DNA-damaging activity as with ionizing radiation or with a chemotherapeutic agent.
    这项发明涉及新型二氢-和四氢萘啶,可用于增强对肿瘤细胞的致死效果,以治疗引起DNA损伤活性的治疗方法,如电离辐射或化学治疗药物。
查看更多